News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
517,475 Results
Type
Article (32475)
Company Profile (93)
Press Release (484907)
Section
Business (150720)
Career Advice (822)
Deals (25617)
Drug Delivery (55)
Drug Development (69043)
Employer Resources (69)
FDA (14138)
Job Trends (11038)
News (263362)
Policy (24722)
Tag
Academia (1944)
Alliances (35139)
Alzheimer's disease (999)
Approvals (14120)
Artificial intelligence (117)
Bankruptcy (214)
Best Places to Work (8817)
Breast cancer (166)
Cancer (1149)
Cardiovascular disease (101)
Career advice (722)
Cell therapy (215)
Clinical research (56540)
Collaboration (335)
Compensation (143)
COVID-19 (2226)
C-suite (90)
Data (1240)
Diabetes (146)
Diagnostics (4455)
Earnings (60595)
Events (77276)
Executive appointments (321)
FDA (14766)
Funding (324)
Gene therapy (149)
GLP-1 (509)
Government (3505)
Healthcare (15170)
Infectious disease (2305)
Inflammatory bowel disease (93)
Interviews (87)
IPO (11788)
Job creations (2561)
Job search strategy (664)
Layoffs (250)
Legal (5107)
Lung cancer (171)
Lymphoma (85)
Manufacturing (117)
Medical device (13187)
Medtech (13191)
Mergers & acquisitions (13970)
Metabolic disorders (411)
Neuroscience (1263)
NextGen Class of 2024 (4888)
Non-profit (3278)
Northern California (1308)
Obesity (237)
Opinion (103)
Parkinson's disease (77)
People (45673)
Phase I (18250)
Phase II (24700)
Phase III (18312)
Pipeline (449)
Postmarket research (2170)
Preclinical (5968)
Radiopharmaceuticals (198)
Rare diseases (201)
Real estate (4016)
Regulatory (17357)
Research institute (1821)
Resumes & cover letters (106)
Southern California (1097)
Startups (2605)
United States (11760)
Vaccines (525)
Weight loss (173)
Date
Last 7 days (204)
Last 30 days (1721)
Last 365 days (27604)
2024 (27557)
2023 (31782)
2022 (41580)
2021 (44760)
2020 (42871)
2019 (36099)
2018 (27592)
2017 (25299)
2016 (24006)
2015 (28684)
2014 (22171)
2013 (18375)
2012 (19727)
2011 (20339)
2010 (19279)
Location
Africa (518)
Arizona (110)
Asia (30700)
Australia (4978)
California (2868)
Canada (1142)
China (249)
Colorado (130)
Connecticut (140)
Europe (64060)
Florida (437)
Georgia (105)
Illinois (314)
Indiana (193)
Japan (83)
Kansas (86)
Maryland (551)
Massachusetts (2155)
Michigan (121)
Minnesota (262)
New Jersey (927)
New York (850)
North Carolina (596)
Northern California (1308)
Ohio (108)
Pennsylvania (722)
South America (734)
Southern California (1097)
Texas (444)
Utah (93)
Washington State (248)
517,475 Results for "dose medical corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
Phio’s Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration
December 19, 2024
·
4 min read
Gene therapy
Patient Death in Rett Syndrome Trial Forces Neurogene to Drop High-Dose Arm
Despite the death, the FDA has allowed Neurogene to forge ahead with the Phase I/II Rett syndrome trial, but using only the lower 1E15 vg dose of its investigational gene therapy NGN-401.
November 22, 2024
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Lilly Lowers Brain Swelling With Modified Dosing of Alzheimer’s Drug Kisunla
Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain swelling of patients in a late-stage trial following an adjusted dosing regimen.
October 30, 2024
·
2 min read
·
Tristan Manalac
Press Releases
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mucopolysaccharidosis Type IIIB in Japan
December 6, 2024
·
5 min read
Drug Development
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China.
June 25, 2024
·
8 min read
Obesity
Lilly Looks to Expand Zepbound Supply by Offering Single-Dose Vials
Through its online pharmacy LillyDirect, Eli Lilly announced Tuesday it will allow patients to purchase single-dose vials of Zepbound—without the autoinjector—at a 50% discount or more versus other incretin obesity treatments.
August 27, 2024
·
3 min read
·
Tristan Manalac
Drug Development
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene Inc. (Nasdaq: NGNE) today announced that the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for female pediatric patients with Rett syndrome, and high-dose NGN-401 has been well-tolerated following dosing in May 2024.
June 18, 2024
·
7 min read
Press Releases
QurAlis’ ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed
November 19, 2024
·
6 min read
Press Releases
Therapeutic Doses of Blood Thinners Decrease Mortality for Hospitalized COVID-19 Patients
December 24, 2024
·
3 min read
Press Releases
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
December 11, 2024
·
7 min read
1 of 51,748
Next
